Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140101 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries
A Phase 2 study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,099
- Enrollment target
NCT00140101 is a Phase 2 study that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,099 participants.
The verdict
NCT00140101, a Phase 2 study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,099 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the safety and efficacy of the ZoMaxx drug-eluting stent in patients with blockage of native coronary arteries. The study is designed to demonstrate non-inferiority to the TAXUS Express2 Paclitaxel-Eluting Stent that has proven superior to bare metal stents and is a recognized standard of care.
Interventions
- DEVICE TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
- DEVICE ZoMaxx™ Drug-Eluting Coronary Stent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,099 participants |
| Start Date | 2005-05 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00140101
The ClinicalTrials.gov registry entry for NCT00140101 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,099 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent is the first listed.
NCT00140101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00140101 about?
NCT00140101 is a clinical study titled "Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries". The purpose of this study is to demonstrate the safety and efficacy of the ZoMaxx drug-eluting stent in patients with blockage of native coronary arteries. The study is designed to demonstrate non-inferiority to the TAXUS Express2 Paclitaxel-Eluting Stent that has proven superior to bare metal stent...
What is the current status of trial NCT00140101?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,099 participants. The study started on 2005-05. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00140101?
The interventions under investigation include: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent (DEVICE), ZoMaxx™ Drug-Eluting Coronary Stent System (DEVICE).
Who is sponsoring clinical trial NCT00140101?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.